Alessio Pecori

Dr. Alessio Pecori

AOU Città della Salute e della Scienza di Torino Hospital, Turin, Piedmont, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Hypertension
Verified
Journal Article
Closed access
FBFabrizio Buffolo
Fabrizio Buffolo
APAlessio Pecori
Alessio Pecori
MPMartin Reincke Prof
Martin Reincke Prof
MOMerve Outland
Merve Outland
FVFranco Veglio
Franco Veglio
SILVIA MONTICONESILVIA MONTICONE
SILVIA MONTICONE
BACKGROUND: About 10% of patients with arterial hypertension have a positive screening test for primary aldosteronism (PA) and 50% to 70% of them have a negative confirmatory test: the appropriate follow-up of these patients is currently unknown. We investigated the incidence of PA in patients with previous negative confirmatory testing, after at least a 2-year follow-up. METHODS: One hundred eighty-four patients with a previously elevated aldosterone-to-renin ratio followed by a negative confirmatory test were recruited in 2 hypertension centers (Torino and Munich). We repeated the screening test for PA and, if positive, the confirmatory test (seated saline infusion test or captopril challenge test). Primary end point of the study was the incidence of newly diagnosed overt PA, as defined by a positive confirmatory test. RESULTS: After a mean follow-up of 5 years, 20% of patients developed overt PA. When subtype diagnosis was offered systematically, one-third of patients displayed unilateral PA. Patients who developed PA showed worsening of blood pressure control and a higher rate of cardiac organ damage, despite similar implementation of antihypertensive therapy, compared with patients without PA. A mild progression of autonomous aldosterone secretion was evident even in patients without confirmed PA but with relatively stable control of blood pressure levels over time. CONCLUSIONS: About one-fifth of patients with a negative confirmatory test develop overt PA over time. A clinical follow-up of patients with a negative confirmatory test is advisable, along with the repetition of PA investigation, primarily in patients with worsening of blood pressure control.

1 January 2021 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
Alessandro CiprianoAlessandro Cipriano
Alessandro Cipriano
NPNaria Park
Naria Park
APAlessio Pecori
Alessio Pecori
ABAlessandra Eugenia Bionda
Alessandra Eugenia Bionda
MBMichele Bardini
Michele Bardini
LGLorenzo Ghiadoni
Lorenzo Ghiadoni

16 August 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
SRSmarti Reel
Smarti Reel
PRParminder Singh Reel
Parminder Singh Reel
ZEZoran Erlic
Zoran Erlic
LALaurence Amar
Laurence Amar
APAlessio Pecori
Alessio Pecori
EJEmily Jefferson
Emily Jefferson
Hypertension is a major global health problem with high prevalence and complex associated health risks. Primary hypertension (PHT) is most common and the reasons behind primary hypertension are largely unknown. Endocrine hypertension (EHT) is another complex form of hypertension with an estimated prevalence varying from 3 to 20% depending on the population studied. It occurs due to underlying conditions associated with hormonal excess mainly related to adrenal tumours and sub-categorised: primary aldosteronism (PA), Cushing’s syndrome (CS), pheochromocytoma or functional paraganglioma (PPGL). Endocrine hypertension is often misdiagnosed as primary hypertension, causing delays in treatment for the underlying condition, reduced quality of life, and costly antihypertensive treatment that is often ineffective. This study systematically used targeted metabolomics and high-throughput machine learning methods to predict the key biomarkers in classifying and distinguishing the various subtypes of endocrine and primary hypertension. The trained models successfully classified CS from PHT and EHT from PHT with 92% specificity on the test set. The most prominent targeted metabolites and metabolite ratios for hypertension identification for different disease comparisons were C18:1, C18:2, and Orn/Arg. Sex was identified as an important feature in CS vs. PHT classification.

24 July 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
NBNikolaos G Bliziotis
Nikolaos G Bliziotis
LKLeo AJ Kluijtmans
Leo AJ Kluijtmans
GTGerjen Tinnevelt
Gerjen Tinnevelt
PRParminder Singh Reel
Parminder Singh Reel
SRSmarti Reel
Smarti Reel
HTHenri JLM Timmers
Henri JLM Timmers
Despite considerable morbidity and mortality, numerous cases of endocrine hypertension (EHT) forms, including primary aldosteronism (PA), pheochromocytoma and functional paraganglioma (PPGL), and Cushing’s syndrome (CS), remain undetected. We aimed to establish signatures for the different forms of EHT, investigate potentially confounding effects and establish unbiased disease biomarkers. Plasma samples were obtained from 13 biobanks across seven countries and analyzed using untargeted NMR metabolomics. We compared unstratified samples of 106 PHT patients to 231 EHT patients, including 104 PA, 94 PPGL and 33 CS patients. Spectra were subjected to a multivariate statistical comparison of PHT to EHT forms and the associated signatures were obtained. Three approaches were applied to investigate and correct confounding effects. Though we found signatures that could separate PHT from EHT forms, there were also key similarities with the signatures of sample center of origin and sample age. The study design restricted the applicability of the corrections employed. With the samples that were available, no biomarkers for PHT vs. EHT could be identified. The complexity of the confounding effects, evidenced by their robustness to correction approaches, highlighted the need for a consensus on how to deal with variabilities probably attributed to preanalytical factors in retrospective, multicenter metabolomics studies.

1 June 2022 in Journal Of Hypertension
Verified
Journal Article
Open access
APAlessio Pecori
Alessio Pecori
FBFabrizio Buffolo
Fabrizio Buffolo
Jacopo BurrelloJacopo Burrello
Jacopo Burrello
GMGiulio Mengozzi
Giulio Mengozzi
FRFrancesca Rumbolo
Francesca Rumbolo
SILVIA MONTICONESILVIA MONTICONE
SILVIA MONTICONE
Objective: Current guidelines recommend to withdraw interfering antihypertensive drugs before to perform a screening test for primary aldosteronism (PA). Recent studies suggested that diagnostic work-up of PA might be performed without withdrawing mineralocorticoid receptor antagonist (MRA) treatment in selected patients, especially when severe hypertension and hypokalemia are difficult to control. We designed a prospective study to evaluate the effects of MRA treatment on aldosterone to renin ratio (ARR) in patients with PA. Design and method: We prospectively recruited 121 patients with confirmed PA and started on canrenone treatment. Eighteen patients were enrolled in a short-term treatment cohort to assess the effects of MRA on aldosterone to renin ratio (ARR) and potassium after 2 and 8 weeks of canrenone therapy. One hundred and two patients were recruited in the long-term treatment cohort to evaluate the effects of canrenone on ARR after 2 to 12 months of MRA therapy. Results: Plasma renin activity and potassium displayed a significant increase, and ARR showed a significant reduction compared with baseline in patients with PA after MRA initiation. These effects were observed both after a short- and a long-term treatment with canrenone, and were progressively more significant after longer periods of therapy and with greater doses of MRA. We demonstrated that canrenone assumption severely impacts on the rate of false-negative screening tests for PA, which raised from 16.7% to 72.5% after 2 weeks and 7–12 months of MRA treatment, respectively. Conclusions: ARR testing for PA screening should not be performed under MRA therapy.